Podcast TCTMD Talking Points

The ATTRibute-CM Trial

September 4, 2024 | Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.

Talking Points · The ATTRibute-CM Trial

Listen to previous episodes | Download via iTunes

TCTMD Talking Points

TCTMD Talking Points

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.